Screening Techniques for Drug Discovery in Alzheimer's Disease

Sandra Maniam,Subashani Maniam

DOI: https://doi.org/10.1021/acsomega.3c07046

IF: 4.1

2024-02-20

ACS Omega

Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible impairment of memory and other cognitive functions of the aging brain. Pathways such as amyloid beta neurotoxicity, tau pathogenesis and neuroinflammatory have been used to understand AD, despite not knowing the definite molecular mechanism which causes this progressive disease. This review attempts to summarize the small molecules that target these pathways using various techniques involving...

chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper attempts to address the challenges in the drug discovery process for Alzheimer's disease (AD). Specifically, the paper focuses on the following aspects:

1. **Pathological Mechanisms of Alzheimer's Disease**:
- The paper reviews the main pathological mechanisms of Alzheimer's disease, including β-amyloid (Aβ) neurotoxicity, tauopathy, and neuroinflammation pathways. Although these pathways have been extensively studied, the exact molecular mechanisms remain unclear.

2. **Development of Drug Screening Technologies**:
- The paper summarizes various high-throughput screening technologies used in recent years for Alzheimer's disease drug discovery, including high-throughput screening (HTS), molecular modeling, customized bioassays, and spectroscopic detection tools. The development of these technologies has greatly accelerated the drug discovery process.

3. **Novel and Evolving Screening Methods**:
- The paper also highlights some recently developed novel and evolving screening methods that have significant application prospects in Alzheimer's disease research. For example, the use of artificial intelligence (AI) and deep learning technologies for drug screening, and the application of CRISPR technology in gene editing.

4. **Small Molecule Inhibitors Targeting Specific Pathways**:
- The paper details the screening methods for small molecule inhibitors targeting the aforementioned main pathological mechanisms (Aβ, tau, and neuroinflammation). For instance, detecting tau oligomer formation using fluorescence resonance energy transfer (FRET) technology, and screening inhibitors of Aβ aggregation using the ThT (Thioflavin T) assay.

5. **Multi-Target Drug Discovery Strategies**:
- The paper discusses the importance of multi-target drug discovery strategies, pointing out that single-target drugs may not fully address the complexity of Alzheimer's disease. Therefore, there is a need to develop drugs that can simultaneously act on multiple pathological mechanisms.

In summary, this paper aims to summarize and evaluate the current progress in the field of Alzheimer's disease drug discovery and propose future research directions to accelerate the development of effective therapeutic drugs.